Prevalence of sexually acquired antiretroviral drug resistance in a community sample of HIV-positive men who have sex with men in New York City

AIDS Patient Care and STDs

Volumn 25, Issue 5, 2011, Pages 287-293

  Goldsamt, Lloyd A ^a   Clatts, Michael C ^b   Parker, Monica M ^c   Colon, Vivian ^b   Hallack, Renee ^c   Messina, Maria G ^a  

^a NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^b UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^c WADSWORTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ADULT; ALCOHOL CONSUMPTION; ANUS INTERCOURSE; ARTICLE; DRUG ABUSE; EJACULATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; PREVALENCE; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; STRUCTURED INTERVIEW; UNITED STATES;

ADULT; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HOMOSEXUALITY, MALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEW YORK CITY; PREVALENCE; QUESTIONNAIRES; RISK FACTORS; RISK-TAKING; SEXUAL PARTNERS; SOCIOECONOMIC FACTORS; UNSAFE SEX;

EID: 79955776160     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2011.0003     Document Type: Article

References (23)

1. van Kesteren NMC, Hospers HJ, Kok G, et al. Sexuality and sexual risk behavior in HIV-positive men who have sex with men. Qual Health Res 2005;15:145-168. (Pubitemid 41358803)
2. Das-Douglas M, Chu P, Santos GM et al. Decreases in community viral load are associated with a reduction in new HIV diagnoses in San Francisco. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2010.
3. Wood E, Kerr T, Marshall BDL, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: Prospective cohort study. Br Med J 2009:338:b1649.
4. Centers for Disease Control and Prevention. Prevalence and awareness of HIV infection among men who have sex with men-21 cities, United States, 2008. MMWR 2010;59:1201-1207.
5. Markowtiz M, Mohri SM, Shet A, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: A case report. Lancet 2005;365:1031-1039.
6. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among people recently infected with HIV. N Engl J Med 2002;347:385-394. (Pubitemid 34851830)
7. van Kesteren NMC, Hospers HJ, Kok G. Sexual risk behavior among HIV-positive men who have sex with men: A literature review. Patient Educ Couns 2007;65:5-20. (Pubitemid 44820760)
8. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999;282;2:1135-1141. (Pubitemid 29441957)
9. Eshleman SH, Husnik M, Hudelson S, et al. Antiretroviral drug resistance, HIV-1 tropism, and HIV-1 subtype among men who have sex with men with recent HIV-1 infection. AIDS 2007;21:1165-1174. (Pubitemid 46763287)
10. Johnson JA, Li JF, Wei X et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLOS Med 2008;5:e158.
11. Parker MM, Gordon D, Reilly A, et al. Prevalence of drugresistant and nonsubtype B HIV strains in antiretroviralnaïve, HIV-infected individuals in New York State. AIDS Patient Care STDs 2007;21:644-653.
12. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naïve HIV-1- infected persons in 10 U.S. cities. J Infect Dis 2004;189:2174-2180. (Pubitemid 38757188)
13. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. J Infect Dis 2005;192:958-966. (Pubitemid 41266791)
14. Cachay ER, Mohín N, Kosakovsky SL, et al. Active methamphetamine use is associated with transmitted drugresistance to non-nucleoside reverse transcriptase inhibitors in individuals with HIV infection of unknown duration. Open AIDS J 2007;1:5-10.
15. Colfax GN, Vittinghoff E, Grant R, et al. Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance. AIDS 2007;21:239-241. (Pubitemid 46036934)
16. Gorbach PM, Drumright LN, Javanbakht M et al. Antiretroviral drug resistance and risk behavior among recently HIV-infected men who have sex with men. J Acquir Immune Defic Syndr 2008;47:639-643. (Pubitemid 351442022)
17. Richman DD, Morton SC, Wrin T, et al. The prevalence of antiretroviral drug resistance in the United States. AIDS 2004;18:1393-1401. (Pubitemid 38925131)
18. Davis WR, Johnson BJ, Randolph D, et al. An enumeration method of determining the prevalence of users and operatives of cocaine and heroin in Central Harlem. Drug Alcohol Depend 2003;72:45-58. (Pubitemid 37255329)
19. Melchior, LA, Huba, GJ, Brown VB, et al. A short depression index for women. Educ Psychol Meas 1993;53:1117-1125.
20. Shafer RW, Warford A, Winters MA, et al. Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals. J Virol Methods 2000;86:143-153. (Pubitemid 30227491)
21. Liu TF, Shafer RW. Web resources for HIV type 1 genotypicresistance test interpretation. Clin Infect Dis 2006;42:1608-1618.
22. Mackie NE, Phillips AN, Kaye S, et al. Antiretroviral drug resistance in HIV-1 infected patients with low-level viremia. J Infect Dis 2010;201:1303-1307.
23. Golin CE, Davis RA, Przybyla SM, et al. Safe Talk, a multicomponent, motivational interviewing-based safer sex counseling program for people living with HIV/AIDS: A qualitative assessment of patients' views. AIDS Patient Care STDs 2010;24:237-245.